Sugi Predict

Sugi Predict / Compounds / Aglepristone

Aglepristone

Aglepristone

SCHEMBL2108967

C/C=C\[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 13/20 0.72
▸ PGR P06401 11/20 0.72
▸ AR P10275 8/20 0.72
▸ CYP3A4 P08684 4/20 0.72
▸ CYP2D6 P10635 3/20 0.72
▸ CYP2C19 P33261 3/20 0.72
▸ CYP2C9 P11712 3/20 0.72
▸ ESR1 P03372 3/20 0.72
▸ CYP1A2 P05177 2/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ TDP1 Q9NUW8 2/20 0.72
▸ LMNA P02545 2/20 0.72
▸ NR3C2 P08235 2/20 0.72
▸ OPRM1 P35372 2/20 0.72
▸ ESR2 Q92731 2/20 0.72
▸ MEN1 O00255 1/20 0.72
▸ TP53 P04637 1/20 0.72
▸ ALOX15 P16050 1/20 0.72
▸ NFKB1 P19838 1/20 0.72
▸ THPO P40225 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aglepristone SCHEMBL16673291 1.00 NR3C1 (0.72) NR3C1PGRARCYP3A4CYP2D6
Aglepristone SCHEMBL13625155 1.00 NR3C1 (0.72) NR3C1PGRARCYP3A4CYP2D6
Aglepristone SCHEMBL9849187 1.00 NR3C1 (0.72) NR3C1PGRARCYP3A4CYP2D6
SCHEMBL9359259 0.94 NR3C1 (0.71) NR3C1PGRARCYP3A4CYP2D6
SCHEMBL9847474 0.94 NR3C1 (0.71) NR3C1PGRARCYP3A4CYP2D6
SCHEMBL20621627 0.92 NR3C1 (0.73) NR3C1PGRARCYP3A4CYP2D6
Lilopristone SCHEMBL21740506 0.92 PGR (0.71) NR3C1PGRARCYP3A4CYP2D6
Lilopristone SCHEMBL21010775 0.92 PGR (0.71) NR3C1PGRARCYP3A4CYP2D6
Lilopristone SCHEMBL21740509 0.92 PGR (0.71) NR3C1PGRARCYP3A4CYP2D6
Lilopristone SCHEMBL10453406 0.92 PGR (0.71) NR3C1PGRARCYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240165130-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2024-05-23 — — US claimed
EP-4312991-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF The Regents Of The University Of Michigan (US) 2024-02-07 — — EP claimed
EP-4157242-A1 COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT Galera Labs, LLC (US) 2023-04-05 — — EP claimed
WO-2022212717-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-10-06 — — WO claimed
US-20220257523-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-08-18 — — US claimed
EP-3999153-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF The Regents Of The University Of Michigan (US) 2022-05-25 — — EP claimed
US-20210299143-A1 USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES Spectral Analytics, Inc. (US) 2021-09-30 — — US claimed
US-20210132069-A1 METHODS OF DETECTING PROGESTERONE RECEPTOR AND OF DETECTING AN EXPRESSION LEVEL NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-05-06 — — US claimed
EP-3622953-B1 COMBINATION TREATMENT OF CANCER SCANDION ONCOLOGY AS (DK) 2021-03-17 — — EP claimed
US-10942183-B2 Methods of detecting progesterone receptor and of detecting an expression level REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-03-09 — — US claimed
US-20140363425-A1 SYSTEMS AND METHODS FOR IDENTIFYING CANCERS HAVING ACTIVATED PROGESTERONE RECEPTORS GRAHAM J DINNY (AU) 2014-12-11 — — US claimed
WO-2013086379-A2 METHODS AND COMPOSITIONS FOR TREATING ANTIPROGESTIN-RESISTANT CANCERS FUNDACION SALES (AR) 2013-06-13 — — WO claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 — — EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 — — WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 — — US claimed
EP-0676203-A1 Pharmaceutical compositions of antiglucocorticoid compounds for treating or preventing symptoms of spontaneous or narcotic-induced withdrawal ROUSSEL UCLAF (FR) 1995-10-11 — — EP claimed
EP-0417003-B1 Use of antiprogestomimetics for stimulating ovulation ROUSSEL UCLAF (FR) 1994-06-29 — — EP claimed
US-5173483-A Administering anti-progestomimetic compound ROUSSEL UCLAF (FR) 1992-12-22 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240165130-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF LIPC, LIPA, FABP4 NR3C1 108/4885PGR 337/4885AR 237/4885
US-20220257523-A1 COMPOSITE DRUG PARTICLES AND USES THEREOF LIPC, FABP4, FABP1 NR3C1 98/4885PGR 249/4885AR 252/4885
US-20210299143-A1 USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES NCOA1, NCOA2, NCOA3 NR3C1 10/4885PGR 210/4885AR 63/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback